# Jubilant Pharmova (JUBLPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/jublpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹935.3
- Change: -1.24%
- As of: 2026-11-06
- 1D return: -1.24%
- 5D return: +1.24%
- 1M return: +0.33%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

JUBLPHARMA (₹935.30) exhibits a weak, range-bound technical structure across daily and monthly horizons as of 2026-11-06. The stock is trading below all key moving averages and the Supertrend on both daily and monthly charts, signaling underlying bearish pressure. However, trend conviction is low, with ADX readings of 17.12 (daily) and 9.62 (monthly), indicating a lack of strong directional momentum. On the weekly timeframe, the setup diverges slightly: while price remains below moving averages, the Supertrend is bullish, suggesting a potential consolidation or counter-trend bounce within a broader downtrend.

Price positioning is neutral-to-low relative to recent ranges, sitting at +53.7% of the 20-day range but only +31.1% of the 50-day range. Immediate resistance lies near ₹943 (pivot, +0.82%) and ₹958 (highs, +2.4–2.5%), while support is found at ₹932 (-0.35%) and ₹917 (-1.96%). The stock has experienced a significant drawdown of -24.3% from its available high, with annualized volatility at +34.5%. An active monthly Inside Bar pattern suggests indecision, while recent daily Doji and Harami formations highlight short-term hesitation. A decisive break above ₹943 with volume would be required to challenge the immediate overhead supply, whereas a close below ₹932 could expose further downside toward ₹914.

- Trend Structure: Bearish on daily/monthly (price below all MAs/Supertrend); Weekly shows mixed signals with bullish Supertrend but bearish MA alignment.
- Momentum & Volatility: Weak trend strength (ADX  18); High volatility (+34.5% annualized) with current drawdown of -24.3%.
- Key Levels: Resistance at ₹943 (pivot) and ₹958 (highs); Support at ₹932 (low) and ₹917 (low).
- Pattern Context: Active monthly Inside Bar indicates consolidation; recent daily Doji/Harami reflect short-term indecision.

- Inside Bar
- Doji
- Outside Bar
- Harami
- Bearish Engulfing Reversal

### News Context

Jubilant Pharmova announced plans on November 3, 2026, to raise ₹800 crore through its maiden local bond issue. The capital is designated for capital expenditure and expansion activities. The bonds carry a three-year tenure with indicative pricing around 8.50% and are expected to be subscribed by mutual funds and asset managers.

- Funding Amount: ₹800 crore via maiden local bond issue
- Purpose: Capital expenditure and expansion
- Terms: Three-year tenure with indicative pricing at ~8.50%
- Investor Base: Expected subscription from mutual funds and asset managers

- [Jubilant Pharmova plans to raise Rs 800 crore via maiden bond issue](https://economictimes.indiatimes.com/markets/bonds/jubilant-pharmova-plans-to-raise-rs-800-crore-via-maiden-bond-issue/articleshow/135478180.cms)

### What Changed

Jubilant Pharmova materially altered its capital structure on November 5, 2026, by raising ₹800 crore through the private placement of non-convertible debentures. The Finance Committee approved the allotment of 80,000 unsecured, rated securities, each with a face value of ₹1,00,000, issued at par. These instruments carry an annual interest rate of 8.50% and have a tenure of three years, maturing on November 5, 2028. While this debt issuance expands the company's funding base, the paid-up share capital remained unchanged at 159,281,139 shares, indicating no dilution to existing equity holders. As of the market close on November 6, 2026, the stock traded at ₹935.30, reflecting a decline from the previous recorded price of ₹949.90.

- On November 5, 2026, Jubilant Pharmova allotted 80,000 non-convertible debentures via private placement, raising ₹800 crore at par value.
- The new debt carries an 8.50% annual interest rate and matures on November 5, 2028, with proposed listing on BSE Limited.
- Paid-up share capital remains stable at 159,281,139 shares, confirming the transaction was purely debt-based without equity dilution.
- As of November 6, 2026, the NSE closing price was ₹935.30, down from the prior level of ₹949.90.

- [Jubilant Pharmova Limited has informed the Exchange regarding allotment of 80000 securities pursuant to Non Convertible Securities at its meeting held on November 05, 2026 |SUBJECT: Allotment of Securities](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05112026222548_JPM_-_Allotment_intimation_signed.pdf)
- [JUBILANT PHARMOVA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261105_224901746.xml)

### Official Filings

Jubilant Pharmova Limited has advanced its debt-raising initiative, moving from proposal to execution. On November 5, 2026, the company’s Finance Committee approved the allotment of ₹800 crore in non-convertible debentures (NCDs) via private placement. These unsecured, rated securities carry an 8.50% annual interest rate, have a three-year tenure maturing on November 5, 2028, and are proposed for listing on the Bombay Stock Exchange. This issuance is part of a broader shareholder-approved mandate allowing up to ₹2,500 crore in NCDs, which received credit rating IND AA+/Stable from India Ratings and Research on October 21, 2026. The paid-up share capital remains unchanged at 159,281,139 shares, indicating no dilution to existing equity holders.

Investors should note that while this specific tranche is complete, the company retains authority to raise additional funds under the same resolution until November 20, 2026. Concurrently, the Board is scheduled to meet on November 13, 2026, to approve financial results for the quarter and half-year ended September 30, 2026. An earnings webinar for investors will follow on November 16, 2026.

- Completed Allotment: ₹800 crore in unsecured NCDs allotted on November 5, 2026, with 8.50% interest and maturity on November 5, 2028.
- Remaining Authority: Shareholder approval permits issuance up to ₹2,500 crore total; e-voting for this mandate closes on November 20, 2026.
- Credit Rating: Proposed NCDs hold an IND AA+/Stable rating assigned by India Ratings and Research on October 21, 2026.
- Upcoming Results: Board meeting for Q2/HFY26 financial results is set for November 13, 2026, followed by an investor webinar on November 16, 2026.

- [Jubilant Pharmova Limited has informed the Exchange regarding allotment of 80000 securities pursuant to Non Convertible Securities at its meeting held on November 05, 2026 |SUBJECT: Allotment of Securities](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05112026222548_JPM_-_Allotment_intimation_signed.pdf)
- [JUBILANT PHARMOVA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261105_224901746.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02112026182907_Jubilant_Pharmova_Disclosure_30102026_Signed.pdf)
- [Board Meeting Intimation |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20261030_172121856.xml)
- [Financial Results |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_30102026172442_Intimation_of_Board_Meeting-_signed.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_23102026154515_Relodgement_of_Shares.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_22102026180510_NO22102026_1.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 47.68 | PUBLIC_VAL: 51.78 | EMPTR: .55 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742546_21102026121458_WEB.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026163219_BSECR.pdf)
- [Jubilant Pharmova Limited has informed the Exchange regarding Notice of Postal Ballot |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026201440_PBNoticeforBSE.pdf)

### Fundamentals

Jubilant Pharmova’s latest quarterly results for Q1 FY2026-27 reveal a sharp sequential deterioration in profitability, despite continued top-line growth. Revenue from operations decreased slightly to ₹2,229.40 crore from ₹2,290 crore in Q4 FY2025-26, while other expenses rose to ₹479.20 crore. This pressure compressed margins significantly, driving Profit Before Tax down sharply to ₹86.40 crore from ₹176 crore and Net Profit falling to ₹56.40 crore from ₹119.30 crore.

However, the underlying annual trajectory remains robust. For the full year ended Mar 2026, sales grew to ₹8,280 crore from ₹7,234 crore, with Operating Profit rising to ₹1,260 crore. Earnings quality has improved markedly, evidenced by Cash from Operating Activity reaching ₹1,227 crore and the Cash Conversion Cycle tightening to 47 days from 124 days in Mar 2024. While TTM net profit has declined to ₹351 crore due to a one-off drop in Other Income (from ₹416 crore to ₹7 crore), core operational efficiency is strengthening. Institutional interest is also shifting, with DIIs increasing their stake to 13.01% as promoter holding stabilized at 47.67%.

- Q1 FY2026-27 Net Profit fell sequentially to ₹56.40 crore from ₹119.30 crore, driven by a drop in PBT to ₹86.40 crore amid rising other expenses of ₹479.20 crore.
- Full-year FY2026 sales grew 14.4% YoY to ₹8,280 crore, with Operating Profit expanding to ₹1,260 crore, indicating strong underlying demand.
- Cash conversion efficiency has improved significantly; CFO reached ₹1,227 crore and the Cash Conversion Cycle narrowed to 47 days from 124 days in Mar 2024.
- DIIs increased their holding to 13.01% in Sep 2026, while promoter stakes remained stable at 47.67%, signaling growing institutional confidence.

### Bear Case

JUBLPHARMA faces a challenging market setup characterized by significant price depreciation and elevated volatility. As of November 6, 2026, the stock has declined 19.4% over the past year and is down 11.6% year-to-date, with a current drawdown of -24.3%. Technical indicators on the daily timeframe are bearish; the Supertrend direction is negative, and the 20-day moving average slope is steeply declining at -8.48%, suggesting persistent selling pressure. The stock closed at ₹935.3, trading below its previous close of ₹947.05, with immediate resistance near ₹942.98. While the weekly trend remains bullish, the monthly trend is also bearish, indicating that medium-term momentum is weakening. Additionally, the company’s plan to raise ₹800 crore via a maiden bond issue introduces debt into its capital structure, which may impact future financial flexibility despite the proceeds being earmarked for capital expenditure.

- Annualized volatility stands at +34.5%, with a maximum historical drawdown of -34.7%, reflecting high risk and price instability.
- Daily technicals show bearish momentum: Supertrend is down, ADX (14) is low at 17.12, and the 20-day EMA slope is -4.49%.
- The stock is currently in a -24.3% drawdown from recent highs, with support levels testing lower at ₹932.02 and ₹916.98.
- The company is raising ₹800 crore through a three-year bond issue at ~8.50% indicative pricing, introducing new leverage.

- [Jubilant Pharmova plans to raise Rs 800 crore via maiden bond issue](https://economictimes.indiatimes.com/markets/bonds/jubilant-pharmova-plans-to-raise-rs-800-crore-via-maiden-bond-issue/articleshow/135478180.cms)
- [Jubilant Pharmova Limited has informed the Exchange regarding allotment of 80000 securities pursuant to Non Convertible Securities at its meeting held on November 05, 2026 |SUBJECT: Allotment of Securities](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05112026222548_JPM_-_Allotment_intimation_signed.pdf)
- [JUBILANT PHARMOVA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261105_224901746.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02112026182907_Jubilant_Pharmova_Disclosure_30102026_Signed.pdf)
- [Board Meeting Intimation |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20261030_172121856.xml)
- [Financial Results |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_30102026172442_Intimation_of_Board_Meeting-_signed.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_23102026154515_Relodgement_of_Shares.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_22102026180510_NO22102026_1.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 47.68 | PUBLIC_VAL: 51.78 | EMPTR: .55 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742546_21102026121458_WEB.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026163219_BSECR.pdf)

### FAQs

**What capital raising activity has Jubilant Pharmova recently completed?**

On November 5, 2026, the company allotted 80,000 non-convertible debentures aggregating Rs 800 crore through private placement. These unsecured, rated securities carry an 8.50% annual interest rate and have a three-year tenure maturing on November 5, 2028. The proceeds are allocated for capital expenditure and expansion.

**How does this debt issuance affect existing shareholders?**

The allotment of debt instruments did not alter the equity structure. As of November 5, 2026, the paid-up share capital and total number of shares remained unchanged at 159,281,139. Consequently, there is no immediate dilution to existing ownership percentages from this specific transaction.

**When will the company release its financial results for Q2 FY27?**

Jubilant Pharmova has scheduled a Board of Directors meeting for November 13, 2026, to approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. An earnings webinar for investors is also planned for November 16, 2026, from 08:30 to 09:30 IST.

**What is the current technical price context for JUBLPHARMA?**

As of November 6, 2026, the stock closed at ₹935.30, reflecting a -1.2% daily return and a -19.4% one-year return. The daily trend is bearish with resistance near ₹942.98 and support at ₹932.02. The stock is currently in a -24.3% drawdown from its peak.

- [Jubilant Pharmova plans to raise Rs 800 crore via maiden bond issue](https://economictimes.indiatimes.com/markets/bonds/jubilant-pharmova-plans-to-raise-rs-800-crore-via-maiden-bond-issue/articleshow/135478180.cms)
- [Jubilant Pharmova Limited has informed the Exchange regarding allotment of 80000 securities pursuant to Non Convertible Securities at its meeting held on November 05, 2026 |SUBJECT: Allotment of Securities](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05112026222548_JPM_-_Allotment_intimation_signed.pdf)
- [JUBILANT PHARMOVA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261105_224901746.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02112026182907_Jubilant_Pharmova_Disclosure_30102026_Signed.pdf)
- [Board Meeting Intimation |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20261030_172121856.xml)
- [Financial Results |Meeting Date: 13-Nov-2026](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_30102026172442_Intimation_of_Board_Meeting-_signed.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_23102026154515_Relodgement_of_Shares.pdf)
- [Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_22102026180510_NO22102026_1.pdf)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 47.68 | PUBLIC_VAL: 51.78 | EMPTR: .55 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 21-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742546_21102026121458_WEB.xml)
- [Jubilant Pharmova Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026163219_BSECR.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹942.98
- Risk regime: Price Risk Requires Attention

### Support levels
- 914.142578125
- 888.6375
- 846.6078125

### Resistance levels
- 958.96923828125
- 960.2125
- 994.36640625

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -1.24% |
| return_10 | -0.32% |
| return_1m | -5.45% |
| return_1y | -19.43% |
| return_20 | +0.33% |
| return_3m | +0.98% |
| return_5 | +1.24% |
| return_6m | -2.22% |
| return_since_start | -13.39% |
| return_ytd | -11.61% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -34.67% |
| annualized_volatility | +34.47% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Profit Falls 45% as Expenses Outpace Revenue Growth; Comprehensive Income Slumps on OCI Swing

Jubilant Pharmova Limited reported a 17% year-on-year increase in revenue to ₹2,229.40 crore in the first quarter of FY2026‑27, but profit before tax fell 44% to ₹86.40 crore and net profit declined 45% to ₹56.40 crore. Other expenses rose 19%, outpacing revenue growth, while a sharp negative swing in other comprehensive income caused total comprehensive income to drop 74% year-on‑year.

## Revenue Performance

Revenue from operations was ₹2,229.40 crore, up 17.3% from ₹1,900.70 crore in Q1 FY2025‑26. On a sequential basis, revenue declined 2.6% from ₹2,290 crore in the immediately preceding quarter (Q4 FY2025‑26).

## Profitability and Margins

Profit before tax fell to ₹86.40 crore, down 44.1% year‑on‑year from ₹154.50 crore and 50.9% from ₹176 crore sequentially. Net profit showed a similarly steep decline, dropping to ₹56.40 crore — 45% below the prior‑year quarter and 52.7% below the preceding quarter.

The profit‑before‑tax margin contracted to 3.9% from 8.1% in Q1 FY2025‑26. The effective tax rate (tax expense as a percentage of profit before tax) rose to 34.7% from 33.6% a year earlier and 32.2% in Q4, contributing modestly to the lower net profit.

## Expense Trends

Other expenses, a major cost item, increased 19.3% year‑on‑year to ₹479.20 crore from ₹401.80 crore. As a percentage of revenue, other expenses moved from 21.1% to 21.5%, absorbing a slightly larger share of sales. Sequentially, they edged up 1.8% from ₹470.50 crore.

Finance costs were ₹54.20 crore, 10.6% higher than ₹49 crore in Q1 FY2025‑26, though they were 4.1% lower than the ₹56.50 crore recorded in the preceding quarter. The year‑on‑year increase added to the expense burden.

## Other Comprehensive Income Swing

Other comprehensive income turned negative at –₹19.10 crore, compared with a positive ₹41.10 crore in the year‑earlier quarter and ₹281.90 crore in Q4. This swing drove total comprehensive income down to ₹37.30 crore, a decline of 74% from ₹143.60 crore year‑on‑year and 91% from ₹401.20 crore sequentially.

## Earnings Per Share

Basic earnings per share fell to ₹3.57, down 45% from ₹6.49 in Q1 FY2025‑26 and 53% from ₹7.55 in Q4. Diluted EPS moved similarly, to ₹3.56.

## Key Takeaway

Revenue grew 17% year‑on‑year, but profit fell sharply because expense increases — notably a 19% rise in other expenses — outpaced revenue growth. The quarter’s result was further reduced by a large negative swing in other comprehensive income, highlighting the combined effect of rising operating costs and non‑operating volatility on overall profitability.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +47.68%
- FII holding: +15.87%
- DII holding: +12.40%
- Mutual fund holding: +8.99%
- Retail holding: +10.73%
- Promoter pledged: +0.00%

### Major reported shareholders

- SPB TRUSTEE COMPANY PVT LTD — +20.08% (Bodies Corporate)
- HSB TRUSTEE COMPANY PVT LTD — +19.00% (Bodies Corporate)
- MILLER HOLDINGS PTE LTD — +3.28% (Bodies Corporate)
- REKHA JHUNJHUNWALA — +3.28%
- BANDHAN SMALL CAP FUND — +3.21%
- MAV MANAGEMENT ADVISORS LLP — +3.15% (Bodies Corporate)
- GOVERNMENT PENSION FUND GLOBAL — +3.10%
- EAST BRIDGE CAPITAL MASTER FUND I LTD — +2.53%
- KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND — +2.41%
- Theleme India Master Fund Limited — +1.89%

## Official filings

- 2026-11-05 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05112026222548_JPM_-_Allotment_intimation_signed.pdf)
- 2026-11-05 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261105_224901746.xml)
- 2026-11-02 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02112026182907_Jubilant_Pharmova_Disclosure_30102026_Signed.pdf)
- 2026-10-30 — Board Meeting Notice: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20261030_172121856.xml)
- 2026-10-30 — Board Meeting Notice: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_30102026172442_Intimation_of_Board_Meeting-_signed.pdf)
- 2026-10-23 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_23102026154515_Relodgement_of_Shares.pdf)
- 2026-10-22 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_22102026180510_NO22102026_1.pdf)
- 2026-10-21 — Shareholding Disclosure: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742546_21102026121458_WEB.xml)
- 2026-10-21 — Credit Rating Update: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026163219_BSECR.pdf)
- 2026-10-21 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_21102026201440_PBNoticeforBSE.pdf)
- 2026-10-21 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_631_WebXMLFile_20261021_202724602.xml)
- 2026-10-14 — Credit Rating Update: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_14102026163455_Jubilant_Pharmova_Credit_Rating_NCD_signed.pdf)
- 2026-10-12 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_12102026123531_Outcome_of_Board_Meeting_12102026.pdf)
- 2026-10-12 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_12102026124001_Outcome_of_Board_Meeting_12102026.pdf)
- 2026-10-12 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261012_165815155.xml)
- 2026-10-12 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_631_WebXMLFile_20261012_173257492.xml)
- 2026-10-08 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_08102026213231_FinalFile08102026.pdf)
- 2026-10-07 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20261007_194748783.xml)
- 2026-10-05 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05102026190249_IntimationReg745signedQ2F.pdf)
- 2026-09-29 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_631_WebXMLFile_20260929_171119580.xml)
- 2026-09-29 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_29092026171506_ClosureofTradingWindowsigned.pdf)
- 2026-09-28 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_28092026185109_Intimation_Reg30_Dividend_Final.pdf)
- 2026-09-11 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_11092026194009_SE_USFDA_September_2026-final_signed.pdf)
- 2026-09-01 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01092026124717_JPM_GSTNotice.pdf)
- 2026-08-28 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_28082026101506_PharmovaStockExchangeDisclosure.pdf)

## News and market events

- 2026-11-03 — Economic Times: **Jubilant Pharmova plans to raise Rs 800 crore via maiden bond issue** — Jubilant Pharmova is raising Rs 800 crore through its maiden local bond issue, with proceeds allocated for capital expenditure and expansion. The bonds carry a three-year tenure with indicative pricing around 8.50% and are expected to be subscribed by mutual funds and asset managers. — [Source](https://economictimes.indiatimes.com/markets/bonds/jubilant-pharmova-plans-to-raise-rs-800-crore-via-maiden-bond-issue/articleshow/135478180.cms)
- 2026-10-23 — Economic Times: **Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say** — Jubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure and refinance project-related liabilities at overseas subsidiaries. The proposed issuance, rated AA+ by India Ratings, could take place before the end of next month, according to two merchant bankers. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-pharmova-eyes-150-million-through-rupee-debt-sale-bankers-say/articleshow/135141652.cms)
- 2026-10-23 — The Hindu: **Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say** — Jubilant Pharmova plans about ₹1,400 crore rupee debt sale to fund capex and refinance overseas project liabilities. — [Source](https://www.thehindubusinessline.com/markets/jubilant-pharmova-eyes-150-million-through-rupee-debt-sale-bankers-say/article71615410.ece)
- 2026-10-23 — The Hindu: **Stock Market Highlights, October 23: Sensex, Nifty extend losses as crude surges to $114, all sectors close in red** — Sensex Today, Nifty 50 | Stock Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 23rd October 2026. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-highlights-23rd-october-2026/article71611889.ece)
- 2026-10-16 — The Hindu: **Jubilant Pharmova approves ₹800 crore NCD issue through private placement** — The pharmaceutical company’s board has cleared the debt issue, with the interest rate to be determined through the bidding process. — [Source](https://www.thehindubusinessline.com/markets/stock-markets/jubilant-pharmova-approves-800-crore-ncd-issue-through-private-placement/article71577738.ece)
- 2026-10-08 — CNBC-TV18: **Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production** — Jubilant Pharmova’s radiopharma business will invest CAD 94.5 million to modernise and expand its Kirkland, Québec facility and double RUBY-FILL production capacity. The Government of Canada will provide CAD 23.8 million in financial support. — [Source](https://www.cnbctv18.com/market/stocks/jubilant-pharmova-share-price-radiopharma-unit-to-invest-cad-94-5-million-to-double-ruby-fill-production-20008052.htm)
- 2026-09-29 — BUSINESS: **Jubilant Pharmova Ltd Surges 10.47%** — Jubilant Pharmova Ltd has added 32.42% over last one month compared to 0.66% fall in BSE Healthcare index and 5.99% drop in the SENSEX — [Source](https://www.business-standard.com/markets/capital-market-news/jubilant-pharmova-ltd-surges-10-47-126092900225_1.html)
- 2026-09-26 — Economic Times: **F&O Talk: 23,270 is a key Nifty hurdle; Sudeep Shah picks 5 stocks, discusses PB Fintech, Turtlemint strategy** — Nifty ended at 23,140.50 after an eighth consecutive weekly decline, with technical indicators remaining bearish. Analysts identify 23,300 as key resistance and 23,000 as options-based support, while Pharma and Healthcare remain relatively stronger amid persistent global market pressures and volatility. — [Source](https://economictimes.indiatimes.com/markets/expert-view/fo-talk-23270-is-a-key-nifty-hurdle-sudeep-shah-picks-5-stocks-discusses-pb-fintech-turtlemint-strategy/articleshow/134501331.cms)
- 2026-09-15 — BUSINESS: **Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma** — Securities in F&O Ban: — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-lalithaa-jewellery-mart-hdfc-bank-kec-international-aurobindo-pharma-126091500114_1.html)
- 2026-09-14 — CNBC-TV18: **Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more** — From HDFC Bank's succession plan to Tata Sons' potential listing and its impact on listed Tata Group stocks and the impact of SEBI's consultation paper on CAS on BSE, Angel One and other brokers, these are the stocks you should watch out for going into Tuesday's trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-15-hdfc-bank-bse-angel-one-tata-group-infosys-tcs-raymond-share-price-19989980.htm)
- 2026-09-11 — CNBC-TV18: **Jubilant Pharmova's US CMO facility gets 'Voluntary Action Indicated' classification** — Shares of Jubilant Pharmova Ltd ended at ₹1,025.65, down by ₹0.050, or 0.0049%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/jubilant-pharmova-share-price-us-cmo-facility-gets-voluntary-action-indicated-classification-19989636.htm)
- 2026-09-08 — Mint: **Raja Venkatraman recommends three stocks for 8 September** — Market expert Raja Venkatraman shares his top stock picks for 8 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-8-september-11788800507147.html)
- 2026-08-28 — Economic Times: **Jubilant Generics receives show-cause notice demanding over Rs 105 cr** — Jubilant Generics received a Rs 105.5 crore GST show-cause notice from Uttarakhand authorities. The notice alleges improper availment of tax refund and Advance Authorisation Scheme benefits. This action pertains to the fiscal years 2020-21 and 2021-22. The company plans to contest the notice and file a detailed reply soon. Jubilant Pharmova expects no significant financial or operational impact. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-generics-receives-show-cause-notice-demanding-over-rs-105-cr/articleshow/133588367.cms)
- 2026-08-24 — MONEYCONTROL: **Buzzing Stocks: Meesho shares slip on block deal; Apollo Tyres gains 2% after UBS upgrade to ‘buy’** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-meesho-shares-slip-on-block-deal-apollo-tyres-gains-2-after-ubs-upgrade-to-buy-14013468.html)
- 2026-08-24 — Economic Times: **Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra** — Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-reliance-industries-bank-of-baroda-power-grid-natco-pharma-and-jsw-infra/articleshow/133444199.cms)
- 2026-08-23 — CNBC-TV18: **Stocks to Watch for August 24: Reliance Industries, NATCO Pharma, Bank of Baroda** — RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-24-reliance-industries-natco-pharma-bank-of-baroda-federal-bank-jubilant-pharmova-apollo-micro-systems-19974715.htm)
- 2026-08-11 — CNBC-TV18: **Gland Pharma to Triveni Turbines: Top stocks to track in trade today** — Today, at market open, some Nifty 500 stocks rallied on strong earnings and bullish brokerage calls, while others slid on weak Q1 numbers. Here's a look at today's top gainers and losers at market open. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-market-open-gland-pharma-jubilant-pharmova-kec-oil-india-19966195.htm)
- 2026-08-11 — MONEYCONTROL: **Jubilant Pharmova shares in focus on mixed Q1 earnings** — Jubilant Pharmova,Jubilant Pharmova share price,Jubilant Pharmova share price live today — [Source](https://www.moneycontrol.com/news/business/markets/jubilant-pharmova-shares-in-focus-on-mixed-q1-earnings-14000617.html)
- 2026-08-10 — CNBC-TV18: **Stocks to Watch for August 11: Vodafone Idea, Bharat Electronics, Gland Pharma, Bosch and more** — From BEL securing additional orders worth ₹541 crore to Lloyds Metals & Energy, KEC International, Vodafone Idea and others reporting their June-quarter results after market hours, these are the stocks likely to remain in focus ahead of Tuesday’s trading session. Ashiana Housing, Allcargo Terminals, Kalyani Forge and others are also due to report results on August 11. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-11-vodafone-idea-bharat-electronics-lloyds-metals-bosch-and-more-19965863.htm)
- 2026-08-10 — CNBC-TV18: **Jubilant Pharmova Q1 profit falls 45% as margins come under pressure** — Jubilant Pharmova’s June quarter profit dropped 45% year-on-year to ₹56.4 crore, even as revenue from operations climbed 17.3% to ₹2,229.4 crore. EBITDA fell 14.4% to ₹248 crore, while EBITDA margin narrowed to 11.1% from 15.2% a year earlier, weighing on the company’s bottom line. — [Source](https://www.cnbctv18.com/market/jubilant-pharmova-q1-profit-falls-45-pc-as-margins-come-under-pressure-19965969.htm)
- 2026-07-16 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today - 16 July 2026** — The Indian stock market ended Wednesday's session on a higher note. Sumeet Bagadia of Choice Broking recommends five breakout stocks to buy today. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-16-july-2026-11784134080670.html)

## Business profile

**Strategic vision:** Integrated global pharmaceutical company with diverse business segments.

### Business segments
- **Radiopharma:** The Radiopharma business segment is involved in the manufacturing and supply of radiopharmaceuticals, operating a network of 46 radio-pharmacies across the United States.
- **Allergy Immunotherapy:** This segment focuses on the manufacturing and supply of allergic extracts and venom products, supplied to markets in the United States, Canada, Europe, and Australia.
- **CDMO Sterile Injectables:** The company provides manufacturing services for sterile fill and finish injectables, including liquid and lyophilization forms, and an ophthalmic portfolio.
- **Contract Research Development and Manufacturing Organisation (CRDMO):** The CRDMO business integrates Drug Discovery Services and CDMO-API operations, providing contract research and development and manufacturing of Active Pharmaceutical Ingredients.
- **Generics:** The Generics business segment is involved in the manufacturing and supply of generic pharmaceutical products.
- **Proprietary Novel Drugs:** Jubilant Therapeutics, part of this business, is a biopharmaceutical company focused on developing therapies for oncology and auto-immune disorders.

### Competitive strengths
- Global presence with manufacturing facilities in regulated markets.
- Integrated operations across multiple pharmaceutical business segments.
- Network of radio-pharmacies across the United States.

## Related stocks

- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%
- [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/jublpharma
Markdown representation: https://faxioms.com/stocks/jublpharma?render=md